December 13, 2016 / 5:44 PM / 8 months ago

BRIEF-Genticel presents final results of phase 2 study of GTl001

Dec 13 (Reuters) - Genticel Sa

* No statistical difference in viral clearance between treatment and placebo groups at any time point over two years

* No difference in incidence of subjects progressing to high-grade cervical lesions between groups

* Company concludes HPV therapeutics development program; remains focused on seeking new drug candidates Source text: bit.ly/2hBhvrJ Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below